Novavax has announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, achieved its primary effectiveness endpoint in the paediatric expansion of its PREVENT-19 pivotal Phase 3 trial.
The company has shared that the vaccine demonstrated 80% efficacy overall at a time when the Delta variant was the predominant circulating strain in the US. The study enrolled 2,247 adolescents aged 12 through 17-years across 73 sites in the US to evaluate safety, effectiveness (immunogenicity), and efficacy of the vaccine.
